<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: acquisition", fill: "#3c1414"},
{source: "1: acquisition", target: "1: Biologic Systems Corp", fill: "#3c1414"},
{source: "1: acquisition", target: "15: successfully integrate", fill: "#000080"},
{source: "15: successfully integrate", target: "15: operations", fill: "#000080"},
{source: "15: operations", target: "15: Natus and Biologic ", fill: "#000080"},
{source: "15: Natus and Biologic ", target: "15: potential benefits", fill: "#000080"},
{source: "15: potential benefits", target: "15: acquisition", fill: "#000080"},
{source: "15: successfully integrate", target: "31: will become increasingly difficult", fill: "#673147"},
{source: "31: will become increasingly difficult", target: "31: expenses as", fill: "#673147"},
{source: "31: expenses as", target: "31: development", fill: "#673147"},
{source: "31: development", target: "31: phototherapy", fill: "#673147"},
{source: "31: phototherapy", target: "31: technologies", fill: "#673147"},
{source: "31: technologies", target: "31: additional applications", fill: "#673147"},
{source: "31: additional applications", target: "31: current technology", fill: "#673147"},
{source: "31: current technology", target: "31: selling activities particularly outside", fill: "#673147"},
{source: "31: selling activities particularly outside", target: "31: additional infrastructure", fill: "#673147"},
{source: "31: additional infrastructure", target: "31: management", fill: "#673147"},
{source: "31: management", target: "31: proportionately", fill: "#673147"},
{source: "31: proportionately", target: "31: profitability", fill: "#673147"},
{source: "31: will become increasingly difficult", target: "119: suppliers become", fill: "#893f45"},
{source: "119: suppliers become", target: "119: supply us with components meeting", fill: "#893f45"},
{source: "119: supply us with components meeting", target: "119: requirements", fill: "#893f45"},
{source: "119: requirements", target: "119: difficult", fill: "#893f45"},
{source: "119: difficult", target: "119: establish additional", fill: "#893f45"},
{source: "119: establish additional", target: "119: replacement suppliers", fill: "#893f45"},
{source: "119: replacement suppliers", target: "119: timely manner", fill: "#893f45"},
{source: "119: suppliers become", target: "145: Furthermore ", fill: "#cf0"},
{source: "145: Furthermore ", target: "145: future products using", fill: "#cf0"},
{source: "145: future products using", target: "145: technology", fill: "#cf0"},
{source: "145: technology", target: "145: requirements", fill: "#cf0"},
{source: "145: requirements", target: "145: seek premarket approval", fill: "#cf0"},
{source: "145: Furthermore ", target: "START_HERE", fill: "#cf0"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Collaborate</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Data_acquisition">Data acquisition</a></td>
      <td>Data acquisition is the process of sampling signals that measure real world physical conditions and converting the resulting samples into digital numeric values that can be manipulated by a computer. Data acquisition systems, abbreviated by the initialisms DAS, DAQ, or DAU, typically convert analog waveforms into digital values for processing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mergers_and_acquisitions">Mergers and acquisitions</a></td>
      <td>In corporate finance, mergers and acquisitions (M&amp;A) are transactions in which the ownership of companies, other business organizations, or their operating units are transferred or consolidated with other entities. As an aspect of strategic management, M&amp;A can allow enterprises to grow or downsize, and change the nature of their business or competitive position.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Knowledge_acquisition">Knowledge acquisition</a></td>
      <td>Knowledge acquisition is the process used to define the rules and ontologies required for a knowledge-based system. The phrase was first used in conjunction with expert systems to describe the initial tasks associated with developing an expert system, namely finding and interviewing domain experts and capturing their knowledge via rules, objects, and frame-based ontologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Rules_of_Acquisition">Rules of Acquisition</a></td>
      <td>In the fictional Star Trek universe, the Rules of Acquisition are a collection of sacred business proverbs of the ultra-capitalist race known as the Ferengi.\nThe first mention of rules in the Star Trek universe was in "The Nagus", an episode of the TV series Star Trek: Deep Space Nine (Season 1, Episode 10).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Target_acquisition">Target acquisition</a></td>
      <td>Target acquisition is the detection and identification of the location of a target in sufficient detail to permit the effective employment of lethal and non-lethal means. The term is used for a broad area of applications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Resource_acquisition_is_initialization">Resource acquisition is initialization</a></td>
      <td>Resource acquisition is initialization (RAII) is a programming idiom used in several object-oriented, statically-typed programming languages to describe a particular language behavior.  In RAII, holding a resource is a class invariant, and is tied to object lifetime.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proposed_acquisition_of_Twitter_by_Elon_Musk">Proposed acquisition of Twitter by Elon Musk</a></td>
      <td>On April 14, 2022, business magnate Elon Musk offered to purchase American social media company Twitter, Inc., for $43 billion, after previously acquiring 9.1 percent of the company's stock for $2.64 billion, becoming its largest shareholder. Twitter had then invited Musk to join their board of directors, which Musk at first accepted before subsequently declining.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Condor">Operation Condor</a></td>
      <td>Operation Condor (Spanish: Operación Cóndor, also known as Plan Cóndor; Portuguese: Operação Condor) was a United States-backed campaign of political repression and state terror involving intelligence operations and assassination of opponents. It was officially and formally implemented in November 1975 by the right-wing dictatorships of the Southern Cone of South America.Due to its clandestine nature, the precise number of deaths directly attributable to Operation Condor is highly disputed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirement">Requirement</a></td>
      <td>In product development and process optimization, a requirement is a singular documented physical or functional need that a particular design, product or process aims to satisfy. It is commonly used in a formal sense in engineering design, including for example in systems engineering, software engineering, or enterprise engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Visa_requirements_for_United_States_citizens">Visa requirements for United States citizens</a></td>
      <td>As of 25 February 2022, Holders of a United States passport could travel to 186 countries and territories without a travel visa, or with a visa on arrival. The United States passport currently ranks 6th in terms of travel freedom (tied with the passports of Czech Republic, Greece, Malta, Norway, and the UK) according to the Henley Passport Index.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_analysis">Requirements analysis</a></td>
      <td>In systems engineering and software engineering, requirements analysis focuses on the tasks that determine the needs or conditions to meet the new or altered product or project, taking account of the possibly conflicting requirements of the various stakeholders, analyzing, documenting, validating and managing software or system requirements.Requirements analysis is critical to the success or failure of a systems or software project. The requirements should be documented, actionable, measurable, testable, traceable, related to identified business needs or opportunities, and defined to a level of detail sufficient for system design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Age_of_candidacy">Age of candidacy</a></td>
      <td>Age of candidacy is the minimum age at which a person can legally hold certain elected government offices. In many cases, it also determines the age at which a person may be eligible to stand for an election or be granted ballot access.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_requirements_document">Market requirements document</a></td>
      <td>A market requirements document (MRD) in project management and systems engineering, is a document that expresses the customer's wants and needs for the product or service.\nIt is typically written as a part of product marketing or product management.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_elicitation">Requirements elicitation</a></td>
      <td>In requirements engineering, requirements elicitation is the practice of researching and discovering the requirements of a system from users, customers, and other stakeholders. The practice is also sometimes referred to as "requirement gathering".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/System_requirements_specification">System requirements specification</a></td>
      <td>A System Requirements Specification (SyRS) (abbreviated SysRS when need to be distinct from a software requirements specification (SRS)) is a structured collection of information that embodies the requirements of a system.A business analyst (BA), sometimes titled system analyst, is responsible for analyzing the business needs of their clients and stakeholders to help identify business problems and propose solutions. Within the systems development life cycle domain, the BA typically performs a liaison function between the business side of an enterprise and the information technology department or external service providers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. Artificial intelligence, Blockchain, Cloud computing, and big Data are regarded as the "ABCD" (four key areas) of FinTech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NATUS MEDICAL INC      ITEM 1A Risk Factors          On January 5, 2006 we completed our <font color="blue">acquisition</font> of Bio-logic Systems Corp</td>
    </tr>
    <tr>
      <td>There are <font color="blue"><font color="blue">numerous risks</font> associated with</font> having completed the <font color="blue">acquisition</font>          The <font color="blue">completion</font> of the <font color="blue">acquisition</font> may not result in improved operating     results for us, or in our achieving <font color="blue">financial condition</font> superior to that     which we would have achieved had we not completed the <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">acquisition</font> could fail to produce the benefits that we anticipate, or could     have other <font color="blue">adverse effects</font> that we currently do not foresee</td>
    </tr>
    <tr>
      <td>In addition,     some of the <font color="blue">assumptions</font> that we have relied upon, such as achievement of     operating synergies, may not be realized</td>
    </tr>
    <tr>
      <td>In this event, the <font color="blue">acquisition</font>     could result in <font color="blue">reduced earnings</font> of Natus as compared to the per-share     earnings that would have been achieved by Natus if the <font color="blue">acquisition</font> had not     occurred</td>
    </tr>
    <tr>
      <td>We  used  virtually all of our <font color="blue">existing cash resources</font> to complete the     <font color="blue">acquisition</font>, and have <font color="blue">also incurred indebtedness under</font> a new credit <font color="blue">facility</font>     for a portion of the <font color="blue">purchase price</font></td>
    </tr>
    <tr>
      <td>This usage of cash has had an adverse     <font color="blue">impact on</font> our liquidity, and <font color="blue">will force us</font> to place more <font color="blue">reliance on cash</font>     <font color="blue">flow from <font color="blue">operations</font></font> for our liquidity</td>
    </tr>
    <tr>
      <td>If our cash <font color="blue">flow from <font color="blue">operations</font></font> is     not sufficient for our needs, our business could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>If     we are required to <font color="blue">seek <font color="blue">additional</font> external financing</font> to support our need     for cash, we may not have access to <font color="blue">financing on terms</font> that are acceptable     to us, or at all</td>
    </tr>
    <tr>
      <td>Alternatively, we may obtain <font color="blue">additional</font> <font color="blue">financing on terms</font>     that are dilutive to <font color="blue">existing holders</font> of our <font color="blue">common stock</font> or that include     covenants that restrict our business, or both</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________    [50]Table of <font color="blue">Contents       </font>We <font color="blue">entered into</font> a senior secured borrowing <font color="blue">facility</font> to obtain a portion of     the funds needed to complete the <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>The loan causes us to incur     <font color="blue">interest charges</font> for such time as the loan is outstanding</td>
    </tr>
    <tr>
      <td>In addition, the     <font color="blue">loan contains various covenants by us</font> that directly or <font color="blue">indirectly restrict</font>     our ability to engage in <font color="blue">activities</font> that we <font color="blue">may otherwise</font> believe to be in     the <font color="blue">best interests</font> of the company</td>
    </tr>
    <tr>
      <td>The loan is <font color="blue">secured by</font> the assets of the     Company,  and  this  security  interest may also <font color="blue">negatively</font> effect our     <font color="blue">flexibility</font> to engage in financing or other <font color="blue">activities</font> in <font color="blue"><font color="blue">future period</font>s</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue"><font color="blue">successfully</font> integrate</font> the <font color="blue">operations</font> of Natus and Bio-logic,     we  may  not  realize  the  <font color="blue">potential benefits</font> of the <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>The     integration of the <font color="blue">operations</font> of Natus and Bio-logic is a time consuming and     <font color="blue">expensive process</font> and <font color="blue">may disrupt</font> our <font color="blue">operations</font> if it is not completed in a     timely and <font color="blue">efficient manner</font></td>
    </tr>
    <tr>
      <td>Bio-logic’s <font color="blue">primary offices</font> are located in     Mundelein, Illinois and it also has employees and <font color="blue">contractors</font> in, among     other  places,  Israel  and  Poland</td>
    </tr>
    <tr>
      <td>The <font color="blue">geographical distance between</font>     Bio-logic’s and our <font color="blue">facilities</font> may further <font color="blue">adversely</font> affect our ability to     integrate these <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If this <font color="blue">integration effort</font> is not successful,     our results of <font color="blue">operations</font> could be harmed, employee morale could decline,     <font color="blue"><font color="blue">key employees</font> could leave</font>, and <font color="blue">customers could cancel existing orders</font> or     choose not to place new ones</td>
    </tr>
    <tr>
      <td>In addition, we may not achieve the synergies     or other benefits of the <font color="blue">acquisition</font> that we anticipate</td>
    </tr>
    <tr>
      <td>We <font color="blue">may encounter</font>     the following <font color="blue">difficult</font>ies, costs and <font color="blue">delays involved</font> in <font color="blue">integrating</font> these     <font color="blue">operations</font>:           •   Failure to <font color="blue">successfully</font> manage <font color="blue"><font color="blue">relationship</font>s</font> with customers and other     important business partners;           •   Failure of customers to continue using the products and services of     the combined company;           •   The loss of <font color="blue">key employees</font>;           •   <font color="blue">Challenges </font><font color="blue">encountered</font> in <font color="blue">managing larger</font>, more <font color="blue">geographically</font>     dispersed <font color="blue">operations</font>;           •   <font color="blue">Diversion </font>of the attention of <font color="blue"><font color="blue">management</font> from</font> other ongoing business     concerns; and           •   <font color="blue">Potential </font><font color="blue">impairment charges incurred</font> to write down the carrying     amount of <font color="blue"><font color="blue">intangible assets</font> generated as</font> a result of the <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>We have a history of losses, variable quarterly results, and <font color="blue">seasonality</font> in     the sale of our products, and may not maintain <font color="blue">profitability</font> in the future          Since our inception, we have <font color="blue">incurred <font color="blue">significant</font> net losses</font>, including net     losses for the years 2002, 2003 and 2004, and we <font color="blue">may incur net losses</font> in the     future</td>
    </tr>
    <tr>
      <td>As  of  <font color="blue">December </font>31,  2005,  we had an <font color="blue">accumulated deficit</font> of     <font color="blue">approximately</font> dlra30dtta8 million</td>
    </tr>
    <tr>
      <td>Additionally, our revenue and operating results     have  <font color="blue">varied <font color="blue"><font color="blue">significant</font>ly from quarter</font></font> to quarter in the past and may     continue to fluctuate in the future</td>
    </tr>
    <tr>
      <td>The following are among the factors     that could cause our revenue, operating results, and margins to fluctuate     <font color="blue"><font color="blue">significant</font>ly from quarter</font> to quarter:           •   <font color="blue">Budgeting </font>cycle of our customers, <font color="blue">particularly</font> <font color="blue">government</font> entities, in     the US and <font color="blue"><font color="blue">international</font>ly</font>;           •   Size and timing of specific sales, such as large purchases of our     devices and systems or our supplies and services, by <font color="blue">government</font> agencies or     hospital systems;           •   Trade-in <font color="blue">allowances</font> or other <font color="blue">concessions</font> in <font color="blue">connection with</font> the     <font color="blue">introduction</font> of <font color="blue">new products</font> or <font color="blue">improvements</font> to <font color="blue">existing products</font>;           •   Length and <font color="blue">unpredictability</font> of our sales cycle, <font color="blue">particularly</font> for our     Neometrics <font color="blue"><font color="blue">products which</font> may</font> have <font color="blue">sales cycles</font> that are longer or <font color="blue">different</font>     from the <font color="blue">sales cycles</font> of our other products; and           •   Marked changes caused <font color="blue">by rapidly evolving <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>In addition, we experience <font color="blue">seasonality</font> in our revenue</td>
    </tr>
    <tr>
      <td>For example, our     <font color="blue">sales typically decline from</font> our <font color="blue">fourth fiscal quarter</font> to our <font color="blue">first fiscal</font>     quarter, due to patterns in the <font color="blue">capital budgeting</font> and <font color="blue">purchasing cycles</font> of     our  current  and  <font color="blue">prospective customers</font>, many of which are <font color="blue">government</font>     agencies</td>
    </tr>
    <tr>
      <td>We may also experience <font color="blue">declining sales</font> in the <font color="blue">third fiscal quarter</font>     due to <font color="blue">summer holiday</font> and <font color="blue">vacation schedules</font></td>
    </tr>
    <tr>
      <td>We anticipate that we                                           24     ______________________________________________________________________    [51]Table of <font color="blue">Contents       </font><font color="blue">will continue</font> to experience these seasonal <font color="blue">fluctuations</font>, which may lead to     <font color="blue">fluctuations</font> in our quarterly operating results</td>
    </tr>
    <tr>
      <td>We believe that you should     not rely on our results of <font color="blue">operations</font> for interim periods as an <font color="blue">indication</font>     of our expected results in any <font color="blue">future period</font></td>
    </tr>
    <tr>
      <td>We anticipate that it <font color="blue">will become <font color="blue">increasingly</font> <font color="blue">difficult</font></font> for us to manage     our <font color="blue">expenses as</font> we:           •   Continue to invest in research and <font color="blue">development</font> to enhance our     hearing-screening and <font color="blue">phototherapy</font> <font color="blue">product lines</font>, the <font color="blue">technologies</font> we     acquired from Bio-logic, and other products and <font color="blue">technologies</font>;           •   Develop <font color="blue"><font color="blue">additional</font> applications</font> for our <font color="blue">current <font color="blue">technology</font></font>;           •   Increase our marketing and selling <font color="blue">activities</font>, <font color="blue">particularly</font> outside     the US;           •   Develop <font color="blue"><font color="blue">additional</font> infrastructure</font> and hire required <font color="blue">management</font> and     other employees to keep pace with our growth         As a result of these factors, we may need to generate <font color="blue">proportionately</font> higher     revenue to maintain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that we will be able     to sustain <font color="blue">profitability</font> in the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> may be <font color="blue">restricted by</font> the terms of our debt, <font color="blue">which could</font>     <font color="blue">adversely</font> affect us          The  credit  <font color="blue">facility</font> that we <font color="blue">entered into</font> to finance a portion of the     <font color="blue">purchase price</font> of Bio-Logic includes a number of <font color="blue">restrictive covenants</font></td>
    </tr>
    <tr>
      <td>These covenants could <font color="blue">adversely</font> affect us by limiting our ability to plan     for  or react to <font color="blue">market conditions</font> or to meet our capital needs</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>covenants will, among other things, restrict our ability to:           •   Incur more debt;           •   Create liens;           •   Pay dividends and make <font color="blue">distributions</font> or <font color="blue">repurchase stock</font>;           •   Make large <font color="blue">capital expenditures</font>; and           •   Merge, <font color="blue">consolidate</font>, or make other changes to our <font color="blue">corporate structure</font>,     or transfer or <font color="blue">sell assets</font></td>
    </tr>
    <tr>
      <td>In addition, our credit <font color="blue">agreement</font> requires us to maintain <font color="blue">certain financial</font>     ratios and meet other <font color="blue">financial covenants</font></td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">comply with</font> these     ratios or <font color="blue">covenants would</font> cause a default that, if not cured or waived,     could result in our being required to repay the <font color="blue">borrowing under</font> our credit     <font color="blue">facility</font> before its due date</td>
    </tr>
    <tr>
      <td>If we are unable to make this repayment or     <font color="blue">otherwise refinance</font> the borrowing, the <font color="blue">lender under</font> our credit <font color="blue">agreement</font>     could  foreclose  on our assets</td>
    </tr>
    <tr>
      <td>If we refinance the <font color="blue">borrowing on less</font>     favorable terms, our results of <font color="blue">operations</font> and <font color="blue">financial condition</font> could be     <font color="blue">adversely</font> impacted by increased costs and rates</td>
    </tr>
    <tr>
      <td>In addition, our failure to     maintain covenants related to our credit <font color="blue">agreement</font> could have an <font color="blue">impact on</font>     our other <font color="blue">contractual arrangements</font> that require us to maintain third-party     credit related covenants</td>
    </tr>
    <tr>
      <td>We may be unable to service our debt          Our ability to make <font color="blue">scheduled payments on</font> or to refinance our <font color="blue">obligations</font>     with  respect  to  our <font color="blue">debt will depend on</font> our financial and operating     performance</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our business <font color="blue">will generate sufficient</font>     cash <font color="blue">flow from <font color="blue">operations</font></font> or that <font color="blue">future borrowings will</font> be available to us     to <font color="blue">enable us</font> to service our debt or to fund our other liquidity needs</td>
    </tr>
    <tr>
      <td>If we     are unable to meet our debt <font color="blue">obligations</font> or fund our other liquidity needs,     we may need to <font color="blue">restructure</font> or refinance all or a portion of our debt or sell     certain  of  our assets</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we would be able to     <font color="blue">restructure</font> or refinance any of our <font color="blue">debt on commercially reasonable terms</font>,     if at all, <font color="blue">which could</font> cause us to <font color="blue">default on</font> our debt <font color="blue">obligations</font> and     impair  our  liquidity</td>
    </tr>
    <tr>
      <td>Any <font color="blue">refinancing</font> of our <font color="blue">debt could</font> be at higher     <font color="blue">interest rates</font> and may require us to <font color="blue">comply with</font> less favorable covenants,     <font color="blue">which could</font> further restrict our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________    [52]Table of <font color="blue">Contents       </font>We have relied, and expect to continue to rely, on sales of our newborn     <font color="blue">screening products</font> for the majority of our revenue, and a decline in sales     of these <font color="blue">products could</font> cause our revenue to fall          We expect that the <font color="blue">revenue from</font> our newborn hearing <font color="blue">screening products</font> will     continue to account for a majority of our revenue for at least the next     year</td>
    </tr>
    <tr>
      <td>Any factors <font color="blue">adversely</font> affecting the pricing of our newborn hearing     <font color="blue">screening devices</font> and related supplies, or demand for our newborn hearing     <font color="blue">screening products</font>, including <font color="blue">physician acceptance</font> or the selection of     competing products, could cause our revenue to decline and our business to     suffer</td>
    </tr>
    <tr>
      <td><font color="blue">In the United States </font>we sell our newborn hearing <font color="blue">screening products</font> in a     <font color="blue">mature market</font>          We <font color="blue">face competition from</font> other companies in all of our <font color="blue">product lines</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue"><font color="blue">competitors</font> range from</font> small privately held companies to <font color="blue">multinational</font>     <font color="blue"><font color="blue">corporation</font>s</font>, and their <font color="blue">product offerings vary</font> in scope and breadth</td>
    </tr>
    <tr>
      <td>We do     not believe that any <font color="blue">single competitor</font> is dominant in any of our product     lines</td>
    </tr>
    <tr>
      <td>We derive a <font color="blue">significant</font> portion of our <font color="blue">revenue from</font> the sale of disposable     supplies that are used with our hearing <font color="blue">screening devices</font></td>
    </tr>
    <tr>
      <td>In the US, we     sell our <font color="blue">supply products</font> in a <font color="blue">mature market</font></td>
    </tr>
    <tr>
      <td>Because these products can     <font color="blue">generate high margins</font>, we expect that our products, <font color="blue">particularly</font> our hearing     screening <font color="blue">supply products</font>, could face increasing competition, including     <font color="blue">competitors</font> offering lower prices, <font color="blue">which could</font> have an <font color="blue">adverse affect on</font> our     revenue and margins</td>
    </tr>
    <tr>
      <td>We  believe  that  our  primary  <font color="blue">competitive</font>  strength  relates to the     <font color="blue">functionality</font> and <font color="blue">re<font color="blue">liability</font></font> of our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitors</font> may</font> have     certain <font color="blue">competitive</font> advantages which include the ability to <font color="blue">devote greater</font>     resources  to  the  <font color="blue">development</font>, promotion and sale of their products</td>
    </tr>
    <tr>
      <td>Consequently, we may need to increase our efforts, and related expenses for     research and <font color="blue">development</font>, to maintain or improve our position</td>
    </tr>
    <tr>
      <td>We expect <font color="blue">recurring sales</font> to our <font color="blue">existing customers</font> to generate a majority     of our revenue in the future, and if our <font color="blue">existing customers</font> do not continue     to <font color="blue">purchase products from us</font>, our <font color="blue">revenue may decline</font></td>
    </tr>
    <tr>
      <td>Our  business could be harmed if our <font color="blue"><font color="blue">competitors</font> <font color="blue">establish cooperative</font></font>     <font color="blue"><font color="blue">relationship</font>s</font> with large medical device vendors or rapidly acquire market     share <font color="blue">through industry consolidation</font>          Large  medical  device  vendors  may  acquire or <font color="blue">establish cooperative</font>     <font color="blue"><font color="blue">relationship</font>s</font> with our <font color="blue">current <font color="blue">competitors</font></font></td>
    </tr>
    <tr>
      <td>We expect that the medical     device industry <font color="blue">will continue</font> to <font color="blue">consolidate</font></td>
    </tr>
    <tr>
      <td>New <font color="blue">competitors</font> or alliances     among <font color="blue"><font color="blue">competitors</font> may</font> emerge and rapidly acquire <font color="blue">significant</font> market share,     <font color="blue">which would harm</font> our business and <font color="blue">financial prospects</font></td>
    </tr>
    <tr>
      <td>Our  operating results may decline if we do not succeed in developing,     acquiring  and <font color="blue">marketing <font color="blue"><font color="blue">additional</font> products</font></font> or improving our existing     products          We intend to develop and acquire <font color="blue"><font color="blue">additional</font> products</font> and <font color="blue">technologies</font> for     the screening, detection, treatment, monitoring and tracking of common     <font color="blue">medical ailments</font></td>
    </tr>
    <tr>
      <td><font color="blue">Developing </font>and acquiring <font color="blue">new products</font>, and improving our     existing  products,  to meet the needs of current and future customers     requires <font color="blue">significant</font> <font color="blue">investments</font> in research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>If we fail to     <font color="blue">successfully</font>  sell  new  products or update our <font color="blue">existing products</font>, our     operating results <font color="blue">may decline as</font> our <font color="blue">existing products</font> reach the end of     their <font color="blue">commercial life cycles</font></td>
    </tr>
    <tr>
      <td>In  order to <font color="blue">accurately</font> recognize revenue on long-term <font color="blue">development</font> and     <font color="blue"><font color="blue">implementation</font> contracts associated with</font> our Neometrics <font color="blue">newborn screening</font>     data <font color="blue">management</font> systems, we must be able to <font color="blue">accurately</font> estimate the total     cost of completing a project</td>
    </tr>
    <tr>
      <td>In arriving at these estimates, we must make     <font color="blue">assumptions</font> about future costs that may prove to be <font color="blue">inaccurate</font></td>
    </tr>
    <tr>
      <td>We recognize <font color="blue">revenue from</font> our Neometrics <font color="blue">newborn screening</font> data <font color="blue">management</font>     systems, which are generally highly configurable, on the percentage of     <font color="blue">completion</font> basis over the <font color="blue">development</font> and <font color="blue">implementation</font>                                           26     ______________________________________________________________________    [53]Table of <font color="blue">Contents       </font>period of the <font color="blue">associated installation</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> and <font color="blue">implementation</font>     <font color="blue">period typically ranges from six</font> to <font color="blue">nine months</font></td>
    </tr>
    <tr>
      <td>In order to determine     percentage of <font color="blue">completion</font>, we must be able to <font color="blue">accurately</font> estimate the total     cost of the <font color="blue">development</font> and <font color="blue">implementation</font> process</td>
    </tr>
    <tr>
      <td>If our estimates of the     future costs to be incurred are understated, our future gross <font color="blue">profit would</font>     be <font color="blue">negatively</font> impacted, and the <font color="blue">impact could</font> be material to our results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If  we  fail  in  our efforts to educate <font color="blue">clinicians</font>, <font color="blue">government</font> agency     personnel, and third-party payors on the <font color="blue"><font color="blue">effective</font>ness</font> of our products we     will not achieve <font color="blue">future sales growth</font>          It  is  critical to the success of our <font color="blue">sales efforts</font> that we educate a     sufficient number of <font color="blue">clinicians</font>, <font color="blue">hospital administrators</font>, and <font color="blue">government</font>     <font color="blue">agencies about</font> our products and the costs and benefits of their use</td>
    </tr>
    <tr>
      <td>The     commercial  success of our products depends upon clinician, <font color="blue">government</font>     agency, and other third-party payor confidence in the economic and clinical     benefits  of  our <font color="blue">products as well as</font> their <font color="blue">comfort with</font> the efficacy,     <font color="blue">re<font color="blue">liability</font></font>, sensitivity, and <font color="blue">specificity</font> of our products</td>
    </tr>
    <tr>
      <td>We believe that     <font color="blue">clinicians</font>  will  not use our products unless they determine, <font color="blue">based on</font>     published peer-reviewed journal articles and experience, that our products     provide an accurate and cost-<font color="blue">effective</font> <font color="blue">alternative</font> to other means of testing     or treatment</td>
    </tr>
    <tr>
      <td>Our <font color="blue">customers may choose</font> to use <font color="blue">competitive</font> products, which     may  be <font color="blue">less expensive</font> or <font color="blue">may provide faster</font> results than our devices</td>
    </tr>
    <tr>
      <td><font color="blue">Clinicians </font>are <font color="blue">traditionally slow</font> to adopt <font color="blue">new products</font>, testing practices,     and clinical treatments, partly because of perceived <font color="blue"><font color="blue">liability</font> risks</font> and the     <font color="blue">uncertainty</font> of third-party <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>If more <font color="blue">clinicians</font>, <font color="blue">government</font>     agencies, and <font color="blue">hospital administrators</font> do not adopt our products, we may not     maintain  <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Factors that may <font color="blue">adversely</font> affect the medical     community’s acceptance of our products include:           •   <font color="blue">Publication </font>of clinical study results that <font color="blue">demonstrate</font> a lack of     efficacy or cost-<font color="blue"><font color="blue">effective</font>ness</font> of our products;           •   <font color="blue">Changing </font><font color="blue">government</font>al and physician group <font color="blue">guidelines</font>;           •   Performance, quality, price, and <font color="blue">total cost</font> of ownership of our     <font color="blue">products relative</font> to other <font color="blue">such products</font>;           •   Our ability to maintain and enhance our existing <font color="blue"><font color="blue">relationship</font>s</font> and to     form new <font color="blue"><font color="blue">relationship</font>s</font> with leading physicians, physician organizations,     hospitals, state <font color="blue">laboratory personnel</font>, and third-party payors;           •   Changes in state and third-party payor <font color="blue">reimbursement</font> policies for our     products; and           •   <font color="blue">Adoption </font>of federal, state and foreign laws mandating or requiring     <font color="blue">universal newborn</font> hearing screening and metabolic screening</td>
    </tr>
    <tr>
      <td>Our plan to expand our <font color="blue">international</font> <font color="blue">operations</font> will result in increased     costs and is subject to <font color="blue">numerous risks</font>; if our efforts are not successful,     this <font color="blue">could harm</font> our business          The <font color="blue">domestic market</font> for our ALGO hearing <font color="blue">screening products</font> is mature and we     plan to expand our <font color="blue"><font color="blue">international</font> sales</font> and <font color="blue">marketing efforts</font> to increase     sales of our products in <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td><font color="blue">Following </font>our <font color="blue">acquisition</font> of     Fischer-Zoth in September 2004, sales of our Echo-Screen OAE device have     <font color="blue">contributed</font> to a <font color="blue">significant</font> portion of our <font color="blue">sales outside</font> the US We have     <font color="blue">only begun over</font> the <font color="blue">past five years</font> to <font color="blue">significant</font>ly develop our <font color="blue">distributor</font>     <font color="blue">sales force outside</font> the US We may not realize <font color="blue">corresponding growth</font> in     <font color="blue">revenue from</font> growth in <font color="blue">international</font> unit sales, due to the <font color="blue">lower average</font>     <font color="blue">selling prices</font> we receive on <font color="blue">sales outside</font> of the US Even if we are able     to <font color="blue">successfully</font> expand our <font color="blue">international</font> selling efforts, we cannot be     certain that we will be able to create or <font color="blue">increase demand</font> for our products     outside of the US Our <font color="blue">international</font> <font color="blue">operations</font> are subject to other risks,     which include:           •   Impact of possible <font color="blue">recessions</font> in economies outside the US;           •   Political and economic <font color="blue">instability</font>, including <font color="blue">instability</font> related to     war and terrorist attacks <font color="blue">in the US </font>and abroad;                                           27     ______________________________________________________________________    [54]Table of <font color="blue">Contents       </font>  •   Contractual provisions governed by foreign law, such as local law     rights to sales commissions by terminated <font color="blue">distributor</font>s;           •   <font color="blue">Dependence </font>of demand for our products on <font color="blue">health care</font> spending by     foreign <font color="blue">government</font>s;           •   Greater <font color="blue"><font color="blue">difficult</font>y</font> in <font color="blue">accounts receivable collection</font> and longer     <font color="blue">collection periods</font>;           •   <font color="blue">Difficulties </font>of staffing and managing foreign <font color="blue">operations</font>;           •   Reduced protection for <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> in some countries     and potentially conflicting <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> of <font color="blue">third parties</font>     under the laws of <font color="blue">various foreign jurisdictions</font>;           •   <font color="blue">Difficulty </font>in obtaining and maintaining foreign <font color="blue">regulatory</font> approval;     and           •   <font color="blue">Attitudes </font>by <font color="blue">clinicians</font>, and cost <font color="blue">reimbursement</font> policies, towards use     of <font color="blue">disposable supplies</font> that are <font color="blue">potentially unfavorable</font> to our business</td>
    </tr>
    <tr>
      <td>If <font color="blue">guidelines</font> mandating universal <font color="blue">newborn screening</font> do not continue to     develop in <font color="blue">foreign countries</font> and <font color="blue">government</font>s do not <font color="blue">mandate testing</font> of all     <font color="blue">newborns as</font> we anticipate, or if those <font color="blue">guidelines</font> have a long phase-in     period, our <font color="blue">revenues may</font> not grow          We estimate that <font color="blue">approximately</font> 90 to 95prca of the <font color="blue">children born</font> <font color="blue">in the US </font>    are currently being tested for hearing prior to discharge from the hospital</td>
    </tr>
    <tr>
      <td>To date, there has <font color="blue">been only</font> limited adoption of newborn hearing screening     prior to hospital discharge by foreign <font color="blue">government</font>s, and the phase-in period     <font color="blue">varies from several months</font> to <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">widespread adoption</font> of     these  <font color="blue">guidelines</font>  depends, in part, on our ability to <font color="blue">educate foreign</font>     <font color="blue">government</font> agencies, neonatologists, pediatricians, third-party payors, and     <font color="blue">hospital administrators</font> about the benefits of universal <font color="blue">newborn screening</font> as     well as the use of our products to perform the screening and monitoring</td>
    </tr>
    <tr>
      <td>Our     revenues  may not grow if <font color="blue">government</font>s do not require <font color="blue">universal newborn</font>     <font color="blue">screening prior</font> to hospital discharge, or if physicians or hospitals are     slow  to <font color="blue">comply with</font> those <font color="blue">guidelines</font>, or if <font color="blue">government</font>s provide for a     lengthy phase-in period for compliance</td>
    </tr>
    <tr>
      <td>Because we rely on <font color="blue">distributor</font>s or sub-<font color="blue">distributor</font>s to sell our products in     most of our <font color="blue">markets outside</font> of the US, our <font color="blue"><font color="blue">revenue could</font> decline</font> if our     existing <font color="blue">distributor</font>s reduce the volume of <font color="blue">purchases from us</font>, or if our     <font color="blue"><font color="blue">relationship</font> with</font> any of these <font color="blue">distributor</font>s is terminated          We <font color="blue">currently rely on</font> our <font color="blue">distributor</font>s or sub-<font color="blue">distributor</font>s for a majority of     our <font color="blue">sales outside</font> the US Our reliance on <font color="blue">international</font> <font color="blue">distributor</font>s has     <font color="blue">increased with</font> our decision in 2004 to close our Japanese <font color="blue">sales subsidiary</font>     and  sell  through  a  <font color="blue">distributor</font>  in  Japan,  and our <font color="blue">acquisition</font> of     Fischer-Zoth, <font color="blue">which sells</font> its <font color="blue">products through</font> <font color="blue">distributor</font>s in Europe and     Asia</td>
    </tr>
    <tr>
      <td>Some  <font color="blue">distributor</font>s also assist us with <font color="blue">regulatory</font> approvals and     <font color="blue">education</font> of <font color="blue">clinicians</font> and <font color="blue">government</font> agencies</td>
    </tr>
    <tr>
      <td>We intend to continue our     efforts  to  increase  our  sales in Europe, Japan and other developed     countries</td>
    </tr>
    <tr>
      <td>If  we fail to sell our <font color="blue">products through</font> our <font color="blue">international</font>     <font color="blue">distributor</font>s, we would experience a decline in <font color="blue">revenues unless</font> we begin to     sell our <font color="blue">products directly</font> in those markets</td>
    </tr>
    <tr>
      <td>We cannot be certain that we     will  be  able to attract new <font color="blue">international</font> <font color="blue">distributor</font>s to market our     <font color="blue">products <font color="blue">effective</font>ly</font> or <font color="blue">provide timely</font> and cost-<font color="blue">effective</font> customer support     and service</td>
    </tr>
    <tr>
      <td>Even if we are successful in selling our <font color="blue">products through</font> new     <font color="blue">distributor</font>s, the rate of growth of our <font color="blue">revenue could</font> be harmed if our     existing <font color="blue">distributor</font>s do not continue to sell a large <font color="blue">dollar volume</font> of our     products</td>
    </tr>
    <tr>
      <td>None of our existing <font color="blue">distributor</font>s are obligated to continue     selling our products</td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue">foreign laws governing</font> our <font color="blue"><font color="blue">relationship</font>s</font> with our     <font color="blue">international</font> <font color="blue">distributor</font>s</td>
    </tr>
    <tr>
      <td>These laws may require us to make payments to     our <font color="blue">distributor</font>s if we terminate our <font color="blue">relationship</font> for any reason, including     for cause</td>
    </tr>
    <tr>
      <td>Some countries require <font color="blue"><font color="blue">termination payments under</font> local law</font> or     <font color="blue">legislation</font>  that  <font color="blue">may supersede</font> our contractual <font color="blue"><font color="blue">relationship</font> with</font> the     <font color="blue">distributor</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">payments could</font> be equal to a year or more of gross profit     on sales of our products that the <font color="blue">distributor</font> would have earned</td>
    </tr>
    <tr>
      <td>We have     terminated our <font color="blue"><font color="blue">relationship</font> with</font> certain <font color="blue">distributor</font>s in the past</td>
    </tr>
    <tr>
      <td>To date,     we have not been required to make any material <font color="blue">termination payments under</font>     <font color="blue">local laws</font></td>
    </tr>
    <tr>
      <td>Any required payments would <font color="blue">adversely</font> affect our operating     results</td>
    </tr>
    <tr>
      <td>28     ______________________________________________________________________    [55]Table of <font color="blue">Contents       </font>Our operating results may suffer because of foreign currency exchange rate     <font color="blue">fluctuations</font> and may require us to engage in <font color="blue">foreign currency hedging</font>          <font color="blue">Substantially </font>all of our <font color="blue">sales contracts</font> to our US <font color="blue">based customers provide</font>     for payment in US dollars</td>
    </tr>
    <tr>
      <td>In addition, sales to most of our <font color="blue">international</font>     <font color="blue">distributor</font>s provide for payment in US dollars</td>
    </tr>
    <tr>
      <td>However, <font color="blue">substantially</font> all     of the revenue and expenses of our <font color="blue">foreign subsidiaries</font> are <font color="blue">denominated</font> in     the <font color="blue">applicable foreign currency</font></td>
    </tr>
    <tr>
      <td>To date we have not undertaken any foreign     <font color="blue">currency hedging transactions</font> and, as a result, our <font color="blue">future revenue</font> and     <font color="blue">expenses may</font> be <font color="blue">unpredictable due</font> to exchange rate <font color="blue">fluctuations</font> that could     result in <font color="blue">foreign exchange gains</font> and <font color="blue">losses associated with</font> the <font color="blue">translation</font>     of assets <font color="blue">denominated</font> in <font color="blue">foreign currencies</font></td>
    </tr>
    <tr>
      <td>If  <font color="blue"><font color="blue">health care</font> providers</font> are not <font color="blue">adequately reimbursed</font> for procedures     conducted with our devices or supplies, or if <font color="blue">reimbursement</font> policies change     <font color="blue">adversely</font>, we may not be <font color="blue">successful marketing</font> and selling <font color="blue">new products</font> or     <font color="blue">technologies</font>          Clinicians, hospitals, and <font color="blue">government</font> agencies are unlikely to purchase our     products if <font color="blue">clinicians</font> are not <font color="blue">adequately reimbursed</font> for the procedures     conducted  with our devices or supplies</td>
    </tr>
    <tr>
      <td>Unless a sufficient amount of     <font color="blue">conclusive</font>,  peer-reviewed  clinical  data about our products has been     published, third-party payors, including insurance companies and <font color="blue">government</font>     agencies,  may  refuse  to provide <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Furthermore, even if     <font color="blue">reimbursement</font> is provided, it may not be adequate to <font color="blue">fully compensate</font> the     <font color="blue">clinicians</font>  or  hospitals</td>
    </tr>
    <tr>
      <td>Some third-party payors may refuse adequate     <font color="blue">reimbursement</font> unless the infant has <font color="blue">demonstrable risk factors</font></td>
    </tr>
    <tr>
      <td>If health     <font color="blue">care providers cannot</font> obtain sufficient <font color="blue">reimbursement</font> from third-party     payors for our products or the <font color="blue">screenings conducted with</font> our products, it is     unlikely that our <font color="blue"><font color="blue">products will</font> ever</font> achieve <font color="blue">significant</font> market acceptance</td>
    </tr>
    <tr>
      <td><font color="blue">Acceptance </font>of our products in <font color="blue">international</font> markets will depend upon the     <font color="blue">availability</font> of adequate <font color="blue">reimbursement</font> or funding within prevailing health     care payment systems</td>
    </tr>
    <tr>
      <td>Reimbursement, funding and <font color="blue"><font color="blue">health care</font> payment systems</font>     vary <font color="blue">significant</font>ly by country</td>
    </tr>
    <tr>
      <td>We may not obtain approvals for <font color="blue">reimbursement</font>     in a <font color="blue">timely manner</font> or at all</td>
    </tr>
    <tr>
      <td><font color="blue">Adverse  </font>changes  in  <font color="blue">reimbursement</font> policies in general <font color="blue">could harm</font> our     business</td>
    </tr>
    <tr>
      <td>We are unable to predict changes in the <font color="blue">reimbursement</font> methods used     by third-party <font color="blue">health care</font> payors, <font color="blue">particularly</font> those in countries and     regions  outside the US For example, some payors are moving toward a     <font color="blue">managed care system</font> in <font color="blue">which providers contract</font> to <font color="blue">provide comprehensive</font>     <font color="blue">health care</font> for a fixed cost per person</td>
    </tr>
    <tr>
      <td>In a <font color="blue">managed care system</font> the cost     of  our  products may not be <font color="blue">incorporated</font> into the overall payment for     <font color="blue">childbirth</font> and newborn care or there may not be adequate <font color="blue">reimbursement</font> for     our products separate from <font color="blue">reimbursement</font> for the procedure</td>
    </tr>
    <tr>
      <td>Unless the cost     of screening or treatment is reimbursed as a standard component of newborn     care, universal screening is unlikely to occur and the number of infants     likely to be <font color="blue">screened with</font> our <font color="blue">products will</font> be <font color="blue">substantially</font> reduced</td>
    </tr>
    <tr>
      <td>If we lose our <font color="blue"><font color="blue">relationship</font> with</font> any supplier of <font color="blue">key product <font color="blue">components</font></font> or     our <font color="blue"><font color="blue">relationship</font> with</font> a <font color="blue">supplier deteriorates</font> or <font color="blue">key <font color="blue">components</font></font> are not     available in <font color="blue">sufficient quantities</font>, our <font color="blue"><font color="blue">manufacturing</font> could</font> be delayed and     our business <font color="blue">could suffer</font>          We contract with <font color="blue">third parties</font> for the supply of some of the <font color="blue"><font color="blue">components</font> used</font>     in our products and the production of our <font color="blue">disposable products</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">relatively few</font>     sources of supply for some of the <font color="blue"><font color="blue">components</font> used</font> in our products and in     some cases we rely entirely on sole-source suppliers</td>
    </tr>
    <tr>
      <td>In addition, the     lead-time involved in the <font color="blue">manufacturing</font> of some of these <font color="blue">components</font> can be     lengthy and unpredictable</td>
    </tr>
    <tr>
      <td>For example, during 2002, we experienced delays     on the part of a supplier to <font color="blue">provide us with volume production</font> of our new     Flexicoupler supplies</td>
    </tr>
    <tr>
      <td>In 2005, we relied on a <font color="blue">single supplier</font> of cables     used in our ALGO hearing <font color="blue">screening devices</font> to help us complete a field     <font color="blue">replacement program</font> of those cables</td>
    </tr>
    <tr>
      <td>If these or other <font color="blue">suppliers become</font>     unwilling or unable to supply us with <font color="blue">components</font> meeting our <font color="blue"><font color="blue">requirement</font>s</font>,     it might be <font color="blue">difficult</font> to <font color="blue">establish <font color="blue">additional</font></font> or <font color="blue">replacement suppliers</font> in a     <font color="blue">timely manner</font>, or at all</td>
    </tr>
    <tr>
      <td>This would cause our <font color="blue">product sales</font> to be disrupted     and our revenue and operating results to suffer</td>
    </tr>
    <tr>
      <td><font color="blue">Replacement </font>or <font color="blue">alternative</font> sources might not be readily obtainable due to     <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> and other <font color="blue">factors applicable</font> to our <font color="blue">manufacturing</font>     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">In<font color="blue">corporation</font>  </font>of <font color="blue">components</font> from a new supplier into our     products may require a new or supplemental filing with applicable <font color="blue">regulatory</font>     <font color="blue">authorities</font> and clearance or                                           29     ______________________________________________________________________    [56]Table of <font color="blue">Contents       </font>approval of the filing before we could resume <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>This process     may take a substantial period of time, and we may not be able to obtain the     <font color="blue">necessary</font>  <font color="blue">regulatory</font>  clearance or approval</td>
    </tr>
    <tr>
      <td>This could create supply     <font color="blue">disruptions</font> that would harm our <font color="blue">product sales</font> and operating results</td>
    </tr>
    <tr>
      <td>Our <font color="blue">sales efforts</font> through group <font color="blue">purchasing organizations</font> and sales to high     <font color="blue">volume purchasers may reduce</font> our average <font color="blue">selling prices</font>, which would reduce     our revenue and gross <font color="blue">profits from</font> these sales          We have entered, and may in the future enter, into <font color="blue">agreement</font>s with customers     who  purchase  <font color="blue">high volumes</font> of our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">agreement</font>s with these     <font color="blue">customers may contain discounts from</font> our normal <font color="blue">selling prices</font> and other     special pricing considerations, <font color="blue">which could</font> cause our revenue and profits to     decline</td>
    </tr>
    <tr>
      <td>In addition, we have <font color="blue">entered into</font> <font color="blue">agreement</font>s to sell our products     to members of GPOs, which negotiate volume <font color="blue">purchase price</font>s for medical     devices  and  supplies for member hospitals, group practices and other     clinics</td>
    </tr>
    <tr>
      <td>While we make <font color="blue">sales directly</font> to GPO members, the members of these     GPOs now receive <font color="blue">volume discounts from</font> our <font color="blue">normal selling price</font> and may     receive other <font color="blue">special pricing considerations from us</font></td>
    </tr>
    <tr>
      <td>Sales to members of     one GPO, Novation, LLC, accounted for <font color="blue">approximately</font> 15prca, 20prca, and 22prca, of     our <font color="blue">total revenue</font> in the <font color="blue">twelve months</font> ended <font color="blue">December </font>31, 2005, 2004 and     2003, respectively</td>
    </tr>
    <tr>
      <td>Sales to members of GPOs accounted for <font color="blue">approximately</font>     28prca,  46prca,  and  39prca  of  our <font color="blue">total revenue</font> during the 12 months ended     <font color="blue">December </font>31, 2005, 2004, and 2003, respectively</td>
    </tr>
    <tr>
      <td>Other of our existing     customers may be members of GPOs with which we do not have <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">sales efforts</font> through GPOs <font color="blue">may conflict with</font> our direct <font color="blue">sales efforts</font> to our     <font color="blue">existing customers</font></td>
    </tr>
    <tr>
      <td>If we enter into <font color="blue">agreement</font>s with new GPOs and some of     our <font color="blue">existing customers</font> begin purchasing our <font color="blue">products through</font> those GPOs, our     revenue and <font color="blue">profits could decline</font></td>
    </tr>
    <tr>
      <td>If  material  <font color="blue">weaknesses</font>  in the adequacy of our <font color="blue"><font color="blue">internal control</font> over</font>     financial  reporting  are  identified  and reported as a result of the     <font color="blue">assessment</font>  required by Section 404 of the Sarbanes-Oxley Act of 2002,     investors  could  lose  confidence in the <font color="blue">re<font color="blue">liability</font></font> of our financial     statements          As <font color="blue">directed by</font> Section 404 of the Sarbanes-Oxley Act of 2002, the Securities     and Exchange Commission <font color="blue">adopted rules</font> requiring <font color="blue">public companies</font> to include     a report of <font color="blue">management</font> on the company’s <font color="blue"><font color="blue">internal control</font> over</font> financial     reporting  in  their  annual  reports  on  Form  10-K We completed an     <font color="blue">implementation</font> project in <font color="blue">preparation</font> for our first Section 404 reporting     <font color="blue">requirement</font> that was <font color="blue">effective</font> for the year ending <font color="blue">December </font>31, 2005 and the     report of <font color="blue">management</font> is <font color="blue">contained herein</font></td>
    </tr>
    <tr>
      <td>This report contains an <font color="blue">assessment</font>     by <font color="blue">management</font> of the <font color="blue"><font color="blue">effective</font>ness</font> of the Company’s <font color="blue"><font color="blue"><font color="blue">internal control</font>s</font> over</font>     financial  reporting</td>
    </tr>
    <tr>
      <td>In  addition, our <font color="blue">independent registered public</font>     <font color="blue">accounting firm</font> that has audited our <font color="blue">financial statements</font> for the year ended     <font color="blue">December </font>31, 2005 also attested to and reported on <font color="blue">management</font>’s <font color="blue">assessment</font>     of the <font color="blue"><font color="blue">effective</font>ness</font> of our <font color="blue"><font color="blue">internal control</font> over</font> financial reporting, as     well as the operating <font color="blue"><font color="blue">effective</font>ness</font> of our <font color="blue"><font color="blue">internal control</font>s</font>, and their     <font color="blue">attestation</font> is <font color="blue">contained herein</font></td>
    </tr>
    <tr>
      <td>While we have expended <font color="blue">significant</font> resources in developing the <font color="blue">necessary</font>     <font color="blue">documentation</font> and <font color="blue">testing procedures</font> required by Section 404, there is a     risk that in the future we will not <font color="blue">comply with</font> all of the <font color="blue"><font color="blue">requirement</font>s</font>     <font color="blue">imposed by</font> Section 404</td>
    </tr>
    <tr>
      <td>If we do not continue to maintain an <font color="blue">effective</font>ly     designed and operating system of <font color="blue">internal control</font>, we may be unable to     <font color="blue">comply with</font> the <font color="blue"><font color="blue">requirement</font>s</font> of Section 404 in the future</td>
    </tr>
    <tr>
      <td>This could result     in an <font color="blue">adverse reaction</font> in the <font color="blue">financial markets due</font> to a loss of confidence     in the <font color="blue">re<font color="blue">liability</font></font> of our <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>Our failure to obtain <font color="blue">necessary</font> FDA <font color="blue">clearances</font> or approvals or to comply     with FDA <font color="blue"><font color="blue">regulations</font> could hurt</font> our ability to <font color="blue">commercially distribute</font> and     market  our products in the US, and this would harm our business and     <font color="blue">financial condition</font>          Unless an exemption applies, each medical device that we wish to market in     the US must first receive one of the <font color="blue">following types</font> of FDA premarket     <font color="blue">review authorizations</font>:           •   <font color="blue">Clearance </font>via Section 510(k) of the federal Food, Drug, and Cosmetics     Act of 1938, as amended; or                                           30     ______________________________________________________________________    [57]Table of <font color="blue">Contents       </font>  •   <font color="blue">Premarket </font><font color="blue">approval via</font> Section 515 of the Food, Drug, and Cosmetics     Act if the FDA has determined that the medical device in <font color="blue">question poses</font> a     <font color="blue">greater risk</font> of injury</td>
    </tr>
    <tr>
      <td>The process of obtaining <font color="blue">premarket approval</font> is much     more costly, lengthy and uncertain</td>
    </tr>
    <tr>
      <td><font color="blue">Premarket </font><font color="blue">approval generally</font> takes from     one to three years, but can take <font color="blue">even longer</font></td>
    </tr>
    <tr>
      <td>The FDA may not <font color="blue">grant either</font>     510(k) clearance or <font color="blue">premarket approval</font> for any product we propose to market</td>
    </tr>
    <tr>
      <td>Furthermore, if the FDA concludes that <font color="blue">future products using</font> our <font color="blue">technology</font>     do not meet the <font color="blue"><font color="blue">requirement</font>s</font> to obtain 510(k) clearance, we would have to     seek <font color="blue">premarket approval</font></td>
    </tr>
    <tr>
      <td>The FDA may impose the more burdensome premarket     approval <font color="blue">requirement</font> on modifications to our <font color="blue">existing products</font> or future     products, which in <font color="blue">either case could</font> be costly and cause us to divert our     attention  and  resources  from the <font color="blue">development</font> of <font color="blue">new products</font> or the     <font color="blue">enhancement</font> of <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>Our  business  may suffer if we are required to revise our labeling or     <font color="blue">promotional materials</font>, or the FDA takes an <font color="blue">enforcement action against us</font> for     off-label uses          We may not promote or advertise the ALGO and Echo-Screen devices, MiniMuffs,     neoBLUE <font color="blue">phototherapy</font> device products, or any <font color="blue">future cleared</font> or approved     devices, for uses not within the scope of our <font color="blue">clearances</font> or approvals or     make <font color="blue">unsupported promotional</font> claims about the benefits of our products</td>
    </tr>
    <tr>
      <td>If     the FDA determines that our claims are outside the scope of our <font color="blue">clearances</font>     or are unsupported it could require us to revise our promotional claims or     take <font color="blue">enforcement action against us</font></td>
    </tr>
    <tr>
      <td>If we were subject to such an <font color="blue">action by</font>     the FDA, our <font color="blue">sales could</font> be delayed, our <font color="blue"><font color="blue">revenue could</font> decline</font>, and our     reputation among <font color="blue">clinicians</font> could be harmed</td>
    </tr>
    <tr>
      <td>Our business would be harmed if the FDA determines that we have failed to     <font color="blue">comply with</font> applicable <font color="blue">regulations</font> or we do not pass an inspection          We are subject to inspection and <font color="blue">market surveillance by</font> the FDA <font color="blue">concerning</font>     compliance with pertinent <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>finds that we     have failed to <font color="blue">comply with</font> these <font color="blue"><font color="blue">requirement</font>s</font>, the Agency can institute a     wide variety of enforcement actions, ranging from a public warning letter to     more <font color="blue">severe sanctions such as</font>:           •   Fines, <font color="blue">injunctions</font> and <font color="blue">civil penalties</font>;           •   Recall or seizure of our products;           •   Issuance of public notices or warnings;           •   <font color="blue">Imposition </font>of operating <font color="blue">restrictions</font>, partial suspension, or total     shutdown of production;           •   Refusal of our requests for 510(k) clearance or <font color="blue">premarket approval</font> of     <font color="blue">new products</font>;           •   <font color="blue">Withdrawal </font>of 510(k) clearance or <font color="blue">premarket approval</font>s already granted;     or           •   Criminal <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td>If we fail to obtain and maintain <font color="blue">necessary</font> foreign <font color="blue">regulatory</font> approvals in     order to market and sell our products outside of the US, we may not be     able to sell our products in other countries          Our products that are <font color="blue">regulated domestically by</font> the FDA are <font color="blue">also regulated</font>     outside the US by foreign <font color="blue">government</font>al agencies similar to the FDA and are     subject to <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> similar to those <font color="blue">of the FDA The </font>time and     cost required to obtain <font color="blue">market authorization from</font> other countries and the     <font color="blue"><font color="blue">requirement</font>s</font>  for  licensing  a  product in another <font color="blue">country may differ</font>     <font color="blue">significant</font>ly from FDA <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>We may not be able to obtain these     approvals without incurring <font color="blue">significant</font> expenses or at all, and we may not     be able to maintain these <font color="blue">approvals once</font> they have been obtained</td>
    </tr>
    <tr>
      <td>31     ______________________________________________________________________    [58]Table of <font color="blue">Contents       </font>If we, or our suppliers, fail to <font color="blue">comply with</font> applicable <font color="blue">regulations</font>, sales     of our <font color="blue">products could</font> be delayed and our <font color="blue">revenue could</font> be harmed          Every <font color="blue">manufacturer</font> of a finished medical device, including Natus and some of     our contract <font color="blue">manufacturer</font>s and suppliers, is required to <font color="blue">demonstrate</font> and     maintain compliance with the FDA’s <font color="blue">quality system regulation</font> and comparable     <font color="blue">regulations</font> of states and other countries</td>
    </tr>
    <tr>
      <td>The FDA enforces the quality     system  regulation  through  periodic  <font color="blue">inspections</font></td>
    </tr>
    <tr>
      <td>We or our contract     <font color="blue">manufacturer</font>s,  may  fail  to  pass  future  <font color="blue">quality system regulation</font>     <font color="blue">inspections</font></td>
    </tr>
    <tr>
      <td>If  we, or our contract <font color="blue">manufacturer</font>s, fail one of these     <font color="blue">inspections</font>  in  the future, our <font color="blue">operations</font> could be disrupted and our     <font color="blue">manufacturing</font> and sales delayed <font color="blue">significant</font>ly until we can <font color="blue">demonstrate</font>     adequate  compliance</td>
    </tr>
    <tr>
      <td>If we or our contract <font color="blue">manufacturer</font>s fail to take     <font color="blue">adequate corrective action</font> in a <font color="blue">timely fashion</font> in response to a quality     <font color="blue">system regulation inspection</font>, the FDA <font color="blue">could shut down</font> our or our contract     <font color="blue">manufacturer</font>s’ <font color="blue">manufacturing</font> <font color="blue">operations</font> or require us, among other things,     to recall our products, either of <font color="blue">which would harm</font> our business</td>
    </tr>
    <tr>
      <td>Governmental, environmental, health and safety <font color="blue">regulations</font> could <font color="blue">adversely</font>     affect our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> are subject to complex and stringent environmental, health,     safety and other <font color="blue">government</font>al laws and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We are subject to a     varied  and  complex  body  of laws and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Existing laws and     <font color="blue">regulations</font> may be revised or <font color="blue">reinterpreted</font>, or new laws and <font color="blue">regulations</font> may     <font color="blue">become applicable</font> to us, that may have a negative effect on our business and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not be successful in <font color="blue">integrating</font> the <font color="blue">businesses</font> that we acquire, or     such <font color="blue">businesses</font> may not be <font color="blue">accretive</font> to earnings or perform as projected          We acquired <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> assets</font> and <font color="blue">technology</font> patents from Pemstar     Pacific Consultants during 2002, and we acquired the assets of Neometrics     Inc</td>
    </tr>
    <tr>
      <td>and affiliated entities during 2003, we acquired Fischer-Zoth in 2004     and we acquired Bio-logic Systems Corp</td>
    </tr>
    <tr>
      <td>We expect to make     <font color="blue">additional</font> <font color="blue">acquisition</font>s of products, <font color="blue">technology</font> assets or <font color="blue">businesses</font> in the     future as part of our efforts to <font color="blue">increase revenue</font> and expand our product     offerings</td>
    </tr>
    <tr>
      <td>In addition to direct costs, <font color="blue">acquisition</font>s pose a number of risks,     including:           •   <font color="blue">Inability </font>to <font color="blue">effective</font>ly integrate acquired products into our     business;           •   Loss of key personnel of the acquired company;           •   Failure to realize expected synergies;           •   Failure of acquired products to achieve projected sales;           •   Failure to maintain customers of, or other <font color="blue"><font color="blue">relationship</font>s</font> existing with     respect to, the acquired business;           •   Failure to <font color="blue">successfully</font> develop the acquired <font color="blue">technology</font> into the     desired products or <font color="blue">enhancement</font>s;           •   <font color="blue">Assumption </font>of unknown <font color="blue">liabilities</font>;           •   Failure to understand and compete <font color="blue">effective</font>ly in markets and with     products or <font color="blue">technologies</font> with which we have limited previous experience; and           •   Write-off of goodwill and <font color="blue">intangible assets</font> related to such     <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>Our <font color="blue">acquisition</font>s of products, <font color="blue">technology</font> assets, or <font color="blue">businesses</font> may have a     negative  <font color="blue">impact on</font> our business if we fail to achieve the anticipated     financial, strategic, and other benefits of <font color="blue">acquisition</font>s or <font color="blue">investments</font>, and     our operating results may suffer because of this</td>
    </tr>
    <tr>
      <td>Future changes in <font color="blue">technology</font> or <font color="blue">market conditions</font> result in <font color="blue"><font color="blue">adjustment</font>s</font> to     our <font color="blue">recorded asset balance</font> for <font color="blue">intangible assets</font>, resulting in <font color="blue">additional</font>     charges that could <font color="blue">significant</font>ly impact our operating results          At  <font color="blue">December </font>31, 2005, we had <font color="blue">significant</font> <font color="blue">intangible assets</font>, including     goodwill and other acquired <font color="blue">intangibles</font></td>
    </tr>
    <tr>
      <td>As a result of our <font color="blue">acquisition</font> of     Bio-logic, these assets will increase <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>The <font color="blue">determination</font> of     related  estimated  <font color="blue">useful lives</font> and whether these assets are impaired     involves <font color="blue">significant</font> judgments</td>
    </tr>
    <tr>
      <td>Our ability                                           32     ______________________________________________________________________    [59]Table of <font color="blue">Contents       </font>to <font color="blue">accurately</font> predict future cash flows related to these <font color="blue">intangible assets</font>     might be hindered by events over which we have no control</td>
    </tr>
    <tr>
      <td>Due to the highly     <font color="blue">competitive</font> nature of the medical device industry, new <font color="blue">technologies</font> could     impair the value of our <font color="blue">intangible assets</font> if they create <font color="blue">market conditions</font>     where our products are no longer <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>Any future <font color="blue">determination</font> that     these assets are carried <font color="blue">at greater than</font> their <font color="blue">fair value could</font> result in     <font color="blue">additional</font> charges, <font color="blue">which could</font> <font color="blue">significant</font>ly impact our operating results</td>
    </tr>
    <tr>
      <td>We  may not be able to preserve the value of our <font color="blue"><font color="blue">intellectual</font> property</font>     because we may not be able to protect access to our <font color="blue"><font color="blue">intellectual</font> property</font> or     we  may lose our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> due to expiration of our     licenses or patents          If  we  fail  to  protect  our  <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> or if our     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> do not <font color="blue">adequately cover</font> the <font color="blue">technology</font> we     employ, other medical device <font color="blue">companies could sell products with</font> features     similar to ours, and this <font color="blue">could reduce demand</font> for our products</td>
    </tr>
    <tr>
      <td>We protect     our <font color="blue"><font color="blue">intellectual</font> property</font> through a <font color="blue">combination</font> of patent, copyright, trade     secret and <font color="blue">trademark laws</font></td>
    </tr>
    <tr>
      <td>Despite our efforts to protect our <font color="blue">proprietary</font>     rights, others may attempt to copy or <font color="blue">otherwise improperly</font> obtain and use     our products or <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Policing <font color="blue">unauthorized use</font> of our <font color="blue">technology</font> is     <font color="blue">difficult</font> and expensive, and we cannot be certain that the steps we have     <font color="blue">taken will prevent misappropriation</font></td>
    </tr>
    <tr>
      <td>Our means of protecting our <font color="blue">proprietary</font>     <font color="blue">rights may</font> be inadequate</td>
    </tr>
    <tr>
      <td><font color="blue">Enforcing </font>our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> could     be costly and time consuming and may divert our <font color="blue">management</font>’s attention and     resources</td>
    </tr>
    <tr>
      <td>Failing to enforce our <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> could also     result in the loss of those rights</td>
    </tr>
    <tr>
      <td>Our  operating results <font color="blue">would suffer</font> if we were subject to a protracted     <font color="blue">infringement</font> claim or a <font color="blue">significant</font> <font color="blue">damage award</font>          The medical <font color="blue">technology</font> industry has, in the past, been characterized by a     substantial amount of <font color="blue">litigation</font> and related <font color="blue">administrative proceedings</font>     regarding patents and <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font></td>
    </tr>
    <tr>
      <td>We expect that medical     screening  products  may  become  <font color="blue">increasingly</font>  subject to third-party     <font color="blue">infringement</font> claims as the number of <font color="blue">competitors</font> in our industry segment     grows and the <font color="blue">functionality</font> of products in <font color="blue">different</font> industry segments     overlaps</td>
    </tr>
    <tr>
      <td>Third parties such as individuals, <font color="blue">education</font>al institutions or     other medical device <font color="blue">companies may</font> claim that we infringe their <font color="blue">intellectual</font>     <font color="blue">property rights</font></td>
    </tr>
    <tr>
      <td>Any claims, with or without merit, could have any of the     <font color="blue">following negative consequences</font>:           •   Result in costly <font color="blue">litigation</font> and <font color="blue">damage award</font>s;           •   Divert our <font color="blue">management</font>’s attention and resources;           •   Cause <font color="blue">product shipment delays</font> or <font color="blue">suspensions</font>; or           •   Require us to seek to <font color="blue">enter into royalty</font> or licensing <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>A successful claim of <font color="blue">infringement</font> against us could result in a substantial     <font color="blue">damage award</font> and <font color="blue">materially harm</font> our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our failure or     <font color="blue">inability</font> to license the infringed or similar <font color="blue">technology</font>, or design and     build non-infringing products, could prevent us from selling our products     and <font color="blue">adversely</font> affect our business and financial results</td>
    </tr>
    <tr>
      <td><font color="blue">Product  </font><font color="blue">liability</font> suits against us could result in expensive and time     consuming <font color="blue">litigation</font>, payment of substantial damages and an increase in our     <font color="blue">insurance rates</font>          The sale and use of our <font color="blue">products could</font> lead to the filing of a product     <font color="blue">liability</font> claim by someone claiming to have <font color="blue">been injured using one</font> of our     products or claiming that one of our <font color="blue">products failed</font> to perform properly</td>
    </tr>
    <tr>
      <td>A     product <font color="blue">liability</font> claim could result in substantial damages and be costly     and time consuming to defend, either of <font color="blue">which could</font> <font color="blue">materially harm</font> our     business or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our product <font color="blue">liability</font> insurance may not     protect  our  assets  from the <font color="blue">financial impact</font> of defending a product     <font color="blue">liability</font> claim</td>
    </tr>
    <tr>
      <td>Any product <font color="blue">liability</font> claim brought against us, with or     without merit, could increase our product <font color="blue">liability</font> <font color="blue">insurance rates</font> or     <font color="blue">prevent us from securing</font> any coverage in the future</td>
    </tr>
    <tr>
      <td>33     ______________________________________________________________________    [60]Table of <font color="blue">Contents       </font>We depend upon <font color="blue">key employees</font> in a <font color="blue">competitive</font> market for <font color="blue">skilled personnel</font>,     and, without <font color="blue">additional</font> employees, we <font color="blue">cannot grow</font> or maintain <font color="blue">profitability</font>          Our products and <font color="blue">technologies</font> are complex, and we depend <font color="blue">substantially</font> on     the <font color="blue">continued service</font> of our senior <font color="blue">management</font> team</td>
    </tr>
    <tr>
      <td>The loss of any of our     <font color="blue">key employees</font> could <font color="blue">adversely</font> affect our business and slow our product     <font color="blue">development</font> process</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success also will depend</font>, in part, on the     <font color="blue">continued service</font> of our key <font color="blue">management</font> personnel, software engineers, and     other research and <font color="blue">development</font> employees and our ability to identify, hire,     and retain <font color="blue">additional</font> personnel, including customer service, marketing, and     <font color="blue">sales staff</font></td>
    </tr>
    <tr>
      <td>Hiring research and <font color="blue">development</font>, engineering, sales, marketing     and <font color="blue">customer service personnel</font> in our industry is very <font color="blue">competitive</font> due to     the limited number of people <font color="blue">available with</font> the <font color="blue">necessary</font> technical skills     and understanding of pediatric audiology, neonatal jaundice <font color="blue">management</font>, and     neonatal  metabolic  screening</td>
    </tr>
    <tr>
      <td>We may be unable to attract and retain     personnel <font color="blue">necessary</font> for the <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">could lose</font> the ability to use net operating loss <font color="blue">carryforwards</font>, which may     <font color="blue">adversely</font> affect our financial results          As of <font color="blue">December </font>31, 2005, we had a <font color="blue">total federal</font> and state net operating loss     <font color="blue">carryforwards</font> of <font color="blue">approximately</font> dlra20dtta4 million and dlra7dtta0 million, respectively,     available  to  reduce  <font color="blue">future taxable income</font></td>
    </tr>
    <tr>
      <td>These net operating loss     <font color="blue">carryforwards</font>, if not utilized to <font color="blue">offset taxable income</font> in <font color="blue"><font color="blue">future period</font>s</font>,     will expire in <font color="blue">various amounts beginning</font> in 2008 through 2025 for state     and/or federal income tax purposes</td>
    </tr>
    <tr>
      <td>If we continue to have net losses, we     may  not  be  able  to  utilize  some or all of our net operating loss     <font color="blue">carryforwards</font> before they expire</td>
    </tr>
    <tr>
      <td>In addition, US income tax law imposes <font color="blue">limitations</font> on the ability of     <font color="blue"><font color="blue">corporation</font>s</font> to use net operating loss <font color="blue">carryforwards</font> if the <font color="blue">corporation</font>     experiences  a more than 50prca change in <font color="blue">ownership during</font> any three-year     period</td>
    </tr>
    <tr>
      <td>We may take actions, such as the issuance of <font color="blue">additional</font> stock, which     would cause an ownership change to occur</td>
    </tr>
    <tr>
      <td>Accordingly, we may be limited to     the amount we can use in any <font color="blue">given year</font>, so even if we have substantial net     income, we may not be able to use our net operating loss <font color="blue">carryforwards</font>     before they expire</td>
    </tr>
    <tr>
      <td>In addition, the net operating loss <font color="blue">carryforwards</font> are     subject to <font color="blue">examination</font> by the Internal Revenue Service (“IRS”), and are thus     subject  to  <font color="blue">adjustment</font>  or  <font color="blue">disallowance</font>  resulting from any such IRS     <font color="blue">examination</font></td>
    </tr>
    <tr>
      <td>We have not undertaken a study to determine <font color="blue">whether such</font>     <font color="blue">limitations</font> exist, and if so, the extent of such <font color="blue">limitations</font></td>
    </tr>
    <tr>
      <td>However, we     believe it is probable that some amount of our net operating <font color="blue">losses will</font> be     affected</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">fully utilize</font> our net operating loss <font color="blue">carryforwards</font>, our     future tax <font color="blue">payments could</font> be higher and our financial results may suffer</td>
    </tr>
    <tr>
      <td>Our <font color="blue">stockholder rights</font> plan and anti-takeover provisions in our charter     <font color="blue">documents</font> and under <font color="blue">Delaware </font>law may make it more <font color="blue">difficult</font> to acquire a     large portion of our securities, to initiate a <font color="blue">tender offer</font> or a proxy     contest, or to acquire us, even though such events may be <font color="blue">beneficial</font> to our     <font color="blue">stockholders</font>          We maintain a <font color="blue">stockholder rights</font> plan that is designed to <font color="blue">deter unsolicited</font>     <font color="blue">takeover activity with respect</font> to our Company</td>
    </tr>
    <tr>
      <td>In addition, provisions of     our <font color="blue">certificate</font> of in<font color="blue">corporation</font> and <font color="blue">bylaws may affect</font> the price of our     <font color="blue">common stock</font>, and could make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to remove     our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Further, these <font color="blue">provisions may</font> make it more <font color="blue">difficult</font> to     acquire a large portion of our securities, to initiate a <font color="blue">tender offer</font> or a     proxy  contest  or  acquire  us,  even  if  doing so <font color="blue">would benefit</font> our     <font color="blue">stockholders</font></td>
    </tr>
  </tbody>
</table>